An atypical lipoteichoic acid from Clostridium perfringens elicits a broadly cross-reactive and protective immune response
Cory Q. Wenzel, Dominic C. Mills, Justyna M. Dobruchowska, J. Vlach, Harald Nothaft, Patrick N. Nation, Parastoo Azadi, Stephen B. Melville, Russell W. Carlson, Mario F. Feldman, Christine M. Szymanski
Abstract
JGS4143 lead to 22% survival, whereas co-gavage with JGS4143 and α-HN13 antiserum resulted in 89% survival. This serum also induced bacterial killing in opsonophagocytosis assays, suggesting that HN13 LTA is an attractive target for future vaccine-development studies.
Topics & Concepts
Clostridium perfringensAntiserumLipoteichoic acidMicrobiologyBiologyAntigenGlycanImmune systemPeptidoglycanMutantGlycoconjugateMolecular biologyBacteriaBiochemistryStaphylococcus aureusImmunologyGlycoproteinGeneGeneticsClostridium difficile and Clostridium perfringens researchAntimicrobial Resistance in StaphylococcusVeterinary medicine and infectious diseases